Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Gene transfer approaches in cancer immunotherapy

Gene Therapy volume 11, pages S18–S25 (2004)Cite this article

Abstract

The idea of enhancing or establishing effective immune response against endogenously developed tumor cells is not novel. More than a hundred years ago, bacterial components were used to develop antitumor immune response. Later, when a number of immune system-effecting cytokines had been discovered, they were used for systemic treatment of cancer patients. However, systemic treatment often resulted in even negative outcome. Recent developments of genetic approaches of cell modifications allowed developing of modern techniques of targeted tumor cell elimination. In the present paper, we review modern trends of the antitumor response enhancement based on immunoregulatory gene transfer into different cell types both in vivo and in vitro. Almost all these approaches are based on the activation of the adaptive arm of the immune system in response to tumor cells. However, recent studies indicate that the innate arm of the immune system, as well as adaptive arm, is involved in tumor suppression. The innate immune system uses nonrearranging germline receptors, which could trigger cellular effector responses that are conditional (or instructive) to the subsequent adaptive immune response. Last years' viewpoints on ‘self’ and ‘non-self’ recognition and primary induction of the immune response have changed. The key role of lymphocytes is pathogen recognition and, following immune response induction, switched on the central role of dendritic cells in ‘non-self’ recognition and induction of both innate and adaptive responses. Moreover, innate response is supposed to be an essential starting point in induction of successful and effective acquired response. Most cancer vaccines do not have ‘non-self’ marks presentation due to their endogenous origin, thus lacking their effectiveness in the induction of the specific long-lasting immune response. Taking this point into consideration, we can conclude that to make cancer vaccine more effective we have to present tumor antigens, together with the molecules that can potentially activate downstream ‘non-self’ recognition events not in parallel, but as a consequence of tumor antigen processing and presentation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Matzinger P . The danger model: a renewed sense of self. Science 2002; 296: 301–305.

    CAS  PubMed  Google Scholar 

  2. Medzhitov R, Janeway Jr CA . Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298–300.

    Article  CAS  PubMed  Google Scholar 

  3. Aderem A, Ulevitch R . Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782–787.

    CAS  PubMed  Google Scholar 

  4. Schnare M et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2: 947–950.

    CAS  PubMed  Google Scholar 

  5. Akira S, Takeda K, Kaisho T . Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675–680.

    CAS  PubMed  Google Scholar 

  6. Van Der Bruggen P et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 51–64.

    CAS  PubMed  Google Scholar 

  7. Scanlan MJ et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 22–32.

    CAS  PubMed  Google Scholar 

  8. Emens LA, Jaffee EM . Cancer vaccines: an old idea comes of age. Cancer Biol Ther 2003; 2: S161–S168.

    PubMed  Google Scholar 

  9. Ohashi PS et al. Ablation of ‘tolerance’ and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991; 65: 305–317.

    CAS  PubMed  Google Scholar 

  10. Miller JF, Morahan G, Allison J . Extrathymic acquisition of tolerance by T lymphocytes. Cold Spring Harb Symp Quant Biol 1989; 54: 807–813.

    CAS  PubMed  Google Scholar 

  11. Gallucci S, Matzinger P . Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13: 114–119.

    CAS  PubMed  Google Scholar 

  12. Pardoll DM . Cancer vaccines. Nat Med 1998; 4: 525–531.

    CAS  PubMed  Google Scholar 

  13. Khong HT, Restifo NP . Natural selection of tumor variants in the generation of ‘tumor escape’ phenotypes. Nat Immunol 2002; 3: 999–1005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lindenmann J, Klein PA . Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med 1967; 126: 93–108.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Fearon ER et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–403.

    CAS  PubMed  Google Scholar 

  16. Gansbacher B et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217–1224.

    CAS  PubMed  Google Scholar 

  17. Hock H et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 1993; 90: 2774–2778.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Tepper RI, Pattengale PK, Leder P . Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503–512.

    CAS  PubMed  Google Scholar 

  19. Golumbek PT et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713–716.

    CAS  PubMed  Google Scholar 

  20. Schmidt-Wolf IG et al. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. Hum Gene Ther 1994; 5: 1161–1168.

    CAS  PubMed  Google Scholar 

  21. Tahara H et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466–6474.

    CAS  PubMed  Google Scholar 

  22. Colombo MP et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173: 889–897.

    CAS  PubMed  Google Scholar 

  23. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–3543.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Restifo NP et al. A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992; 175: 1423–1431.

    CAS  PubMed  Google Scholar 

  25. Rosenberg SA . Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380–384.

    CAS  PubMed  Google Scholar 

  26. Bubenik J et al. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett 1988; 19: 279–282.

    CAS  PubMed  Google Scholar 

  27. Zitvogel L et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995; 55: 1393–1403.

    Google Scholar 

  28. Steinman RM, Cohn ZA . Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137: 1142–1162.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Timmerman JM, Levy R . Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50: 507–529.

    CAS  PubMed  Google Scholar 

  30. Boczkowski D, Nair SK, Snyder D . Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465–472.

    CAS  PubMed  Google Scholar 

  31. Heiser A et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000; 164: 5508–5514.

    CAS  PubMed  Google Scholar 

  32. Morse MA et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003; 21: 341–349.

    CAS  PubMed  Google Scholar 

  33. Thornburg C et al. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. J Immunother 2000; 23: 412–418.

    CAS  PubMed  Google Scholar 

  34. Nishioka Y et al. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999; 59: 4035–4041.

    CAS  PubMed  Google Scholar 

  35. Rosenberg SA, Spiess P, Lafreniere R . A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–1321.

    CAS  PubMed  Google Scholar 

  36. Arakawa F et al. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity. Anticancer Res 2002; 22: 4285–4289.

    CAS  PubMed  Google Scholar 

  37. Gritzapis AD, Mamalaki A, Kretsovali A . Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells. Br J Cancer 2003; 88: 1292–1300.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Trompeter HI et al. Rapid and highly efficient gene transfer into natural killer cells by nucleofection. J Immunol Methods 2003; 274: 245–256.

    CAS  PubMed  Google Scholar 

  39. Schirrmann T, Pecher G . Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther 2002; 9: 390–398.

    CAS  PubMed  Google Scholar 

  40. Gussow D, Seemann G . Humanization of monoclonal antibodies. Methods Enzymol 1991; 203: 99–121.

    CAS  PubMed  Google Scholar 

  41. Hudson PJ . Recombinant antibodies: a novel approach to cancer diagnosis and therapy. Expert Opin Investig Drugs 2000; 9: 1231–1242.

    CAS  PubMed  Google Scholar 

  42. Perez N et al. Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation. Genet Vaccines Ther 2004; 2: 2.

    PubMed  PubMed Central  Google Scholar 

  43. Tjelle TE et al. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther 2004; 9: 328–336.

    CAS  PubMed  Google Scholar 

  44. Wolff JA et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465–1468.

    CAS  PubMed  Google Scholar 

  45. Tang DC, DeVit M, Johnston SA . Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152–154.

    CAS  PubMed  Google Scholar 

  46. Krieg AM . CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709–760.

    CAS  PubMed  Google Scholar 

  47. Wang B et al. Vaccination against pathogenic cells by DNA inoculation. Curr Top Microbiol Immunol 1998; 226: 21–35.

    CAS  PubMed  Google Scholar 

  48. Donnelly JJ et al. DNA vaccines. Annu Rev Immunol 1997; 15: 617–648.

    CAS  PubMed  Google Scholar 

  49. Irvine KR et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996; 156: 238–245.

    CAS  PubMed  Google Scholar 

  50. Diefenbach A, Raulet DH . The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002; 188: 9–21.

    CAS  PubMed  Google Scholar 

  51. Ruzek MC et al. Adenoviral vectors stimulate murine natural killer cell responses and demonstrate antitumor activities in the absence of transgene expression. Mol Ther 2002; 5: 115–124.

    CAS  PubMed  Google Scholar 

  52. Rudginsky S et al. Antitumor activity of cationic lipid complexed with immunostimulatory DNA. Mol Ther 2001; 4: 347–355.

    CAS  PubMed  Google Scholar 

  53. Ma Y et al. Antitumor activity of mannan-binding protein in vivo as revealed by a virus expression system: mannan-binding protein dependent cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1999; 96: 371–375.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Biragyn A et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001; 167: 6644–6653.

    CAS  PubMed  Google Scholar 

  55. Larin SS et al. Immunotherapy with autologous tumor cells engineered to secrete Tag7/PGRP, an innate immunity recognition molecule. J Gene Med 2004; 6: 798–808.

    CAS  PubMed  Google Scholar 

  56. Fushimi T et al. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 2000; 105: 1383–1393.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Sfondrini L et al. Anti-tumor immunity induced by murine melanoma cells transduced with the Mycobacterium tuberculosis gene encoding the 38-kDa antigen. Gene Therapy 1998; 5: 247–252.

    CAS  PubMed  Google Scholar 

  58. Mule JJ et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 1996; 7: 1545–1553.

    CAS  PubMed  Google Scholar 

  59. Pulaski BA, Ostrand-Rosenberg S . Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58: 1486–1493.

    CAS  PubMed  Google Scholar 

  60. Fenton RT et al. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. Hum Gene Ther 1995; 6: 87–106.

    CAS  PubMed  Google Scholar 

  61. Zitvogel L et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996; 26: 1335–1341.

    CAS  PubMed  Google Scholar 

  62. Nabel GJ et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA–liposome complexes. Proc Natl Acad Sci USA 1996; 93: 15388–15393.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Simons JW et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537–1546.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Kircheis R et al. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2+IFN-gamma. Cytokines Cell Mol Ther 1998; 4: 95–103.

    CAS  PubMed  Google Scholar 

  65. Chong H et al. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Therapy 1998; 5: 223–232.

    CAS  PubMed  Google Scholar 

  66. Parney IF et al. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum Gene Ther 1997; 8: 1073–1085.

    CAS  PubMed  Google Scholar 

  67. Zitvogel L et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996; 26: 1335–1341.

    CAS  PubMed  Google Scholar 

  68. Pulaski BA et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000; 60: 2710–2715.

    CAS  PubMed  Google Scholar 

  69. Kiselev SL et al. Molecular cloning and characterization of the mouse tag7 gene encoding a novel cytokine. J Biol Chem 1998; 273: 18633–18639.

    CAS  PubMed  Google Scholar 

  70. Kang D et al. A peptidoglycan recognition protein in innate immunity conserved from insects to humans. Proc Natl Acad Sci USA 1998; 95: 10078–10082.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Kibardin AV et al. Molecular cloning of a new mouse gene tagL containing a lysozyme-like domain. Dokl Biochem 2000; 372: 103–105.

    CAS  PubMed  Google Scholar 

  72. Werner T et al. A family of peptidoglycan recognition proteins in the fruit fly Drosophila melanogaster. Proc Natl Acad Sci USA 2000; 97: 13772–13777.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Liu C et al. Peptidoglycan recognition proteins: a novel family of four human innate immunity pattern recognition molecules. J Biol Chem 2001; 276: 34686–34694.

    CAS  PubMed  Google Scholar 

  74. Rehman A et al. The cloning of a rat peptidoglycan recognition protein (PGRP) and its induction in brain by sleep deprivation. Cytokine 2001; 13: 8–17.

    CAS  PubMed  Google Scholar 

  75. Tydell CC et al. Isolation, characterization, and antimicrobial properties of bovine oligosaccharide binding protein: a microbicidal granule protein of eosinophils and neutrophils. J Biol Chem 2002; 277: 19658–19664.

    CAS  PubMed  Google Scholar 

  76. Sashchenko LP et al. Peptidoglycan recognition protein tag7 forms a cytotoxic complex with heat shock protein 70 in solution and in lymphocytes. J Biol Chem 2004; 279: 2117–2124.

    CAS  PubMed  Google Scholar 

  77. Lo D et al. Peptidoglycan recognition protein expression in mouse Peyer's Patch follicle associated epithelium suggests functional specialization. Cell Immunol 2003; 224: 8–16.

    CAS  PubMed  Google Scholar 

  78. Mirkina II et al. Cloning and study of novel mammalian genes with structural homology with phage lysozyme. Genetika 2000; 36: 1492–1500.

    CAS  PubMed  Google Scholar 

  79. Kibardin AV et al. The differentially spliced mouse tagL gene, homolog of tag7/PGRP gene family in mammals and Drosophila, can recognize Gram-positive and Gram-negative bacterial cell wall independently of T phage lysozyme homology domain. J Mol Biol 2003; 326: 467–474.

    CAS  PubMed  Google Scholar 

  80. Yoshida H, Kinoshita K, Ashida M . Purification of a peptidoglycan recognition protein from hemolymph of the silkworm, Bombyx mori. J Biol Chem 1996; 271: 13854–13860.

    CAS  PubMed  Google Scholar 

  81. Michel T et al. Drosophila Toll is activated by Gram-positive bacteria through a circulating peptidoglycan recognition protein. Nature 2001; 414: 756–759.

    CAS  PubMed  Google Scholar 

  82. Gottar M et al. The Drosophila immune response against Gram-negative bacteria is mediated by a peptidoglycan recognition protein. Nature 2002; 416: 640–644.

    CAS  PubMed  Google Scholar 

  83. Werner T et al. Functional diversity of the Drosophila PGRP-LC gene cluster in the response to lipopolysaccharide and peptidoglycan. J Biol Chem 2003; 278: 26319–26322.

    CAS  PubMed  Google Scholar 

  84. Choe KM et al. Requirement for a peptidoglycan recognition protein (PGRP) in Relish activation and antibacterial immune responses in Drosophila. Science 2002; 296: 359–362.

    CAS  PubMed  Google Scholar 

  85. Ramet M et al. Functional genomic analysis of phagocytosis and identification of a Drosophila receptor for E. coli. Nature 2002; 416: 644–648.

    CAS  PubMed  Google Scholar 

  86. Moiseynko VM et al. Phase I/II trial of gene therapy with the autologous tumor cells modified with the tag7/PGRP-S gene in patients with the disseminated solid tumors. Ann Oncol 2004, (in press).

Download references

Acknowledgements

We thank Mauro Mezzina for helpful suggestions and for kind patience during all stages of manuscript preparation and reviewing. Studies by the authors that are reported here have been supported by grants from the Moscow Anticancer Program, Russian Foundation for Basic Research and Frontiers in Genetics.

Author information

Authors and Affiliations

  1. Institute of Gene Biology Russian Academy of Sciences, Moscow, Russia

    S S Larin, G P Georgiev & S L Kiselev

Authors
  1. S S Larin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G P Georgiev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S L Kiselev
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Larin, S., Georgiev, G. & Kiselev, S. Gene transfer approaches in cancer immunotherapy. Gene Ther 11 (Suppl 1), S18–S25 (2004). https://doi.org/10.1038/sj.gt.3302365

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302365

Keywords

This article is cited by

Search

Advanced search

Quick links